Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 17/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Picumeterol SCHEMBL29414334 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10416913 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL156907 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9857897 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10391329 | 0.99 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10418436 | 0.96 | SLC2A1 (0.59) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10416519 | 0.96 | SLC2A1 (0.59) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL9741835 | 0.96 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9858096 | 0.93 | SLC2A1 (0.68) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9325626 | 0.93 | SLC2A1 (0.54) | SLC2A1ADRB2ADRB1SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 963 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | claimed |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | claimed |
| EP-3238708-A1 | INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-1732512-B1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-9078885-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2015-07-14 | — | — | US | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1133284-A1 | NEW PROCESS | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | claimed |
| US-6221398-B1 | Process for the preparation of respirable particles | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | claimed |
| EP-1075278-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY | AstraZeneca UK Limited (GB) | 2001-02-14 | — | — | EP | claimed |
| WO-2000030614-A1 | A PROCESS FOR PRODUCING PARTICLES WITH A CONVERTED AMORPHOUS AND/OR META-STABLE CRYSTALLINE REGION INTO CRYSTALLINE STATE | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | claimed |
| WO-2000030613-A1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | claimed |
| WO-1999036095-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 1999-07-22 | — | — | WO | claimed |
| CN-1170356-A | Aerosol drug formulations | ASTRA AB (SE) | 1998-01-14 | — | — | CN | claimed |
| EP-0806940-A1 | AEROSOL DRUG FORMULATIONS | Astra Aktiebolag (SE) | 1997-11-19 | — | — | EP | claimed |
| WO-1996019198-A1 | AEROSOL DRUG FORMULATIONS | ASTRA AKTIEBOLAG (SE) | 1996-06-27 | — | — | WO | claimed |
| EP-0460924-A1 | Dichloroaniline compound | GLAXO GROUP LIMITED (GB) | 1991-12-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | SLC2A1 1138/4885ADRB2 3813/4885ADRB1 3375/4885 |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | SLC2A1 4198/4885ADRB2 1076/4885ADRB1 805/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | SLC2A1 2498/4885ADRB2 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.